Immune therapeutic targeting of glioma cancer stem cells

Mustafa Aziz Hatiboglu; Jun Wei; Adam Sauh Gee Wu; Amy B. Heimberger

doi:10.1007/s11523-010-0151-8

Immune therapeutic targeting of glioma cancer stem cells

Mustafa Aziz Hatiboglu, Jun Wei, Adam Sauh Gee Wu, Amy B. Heimberger

Neurosurgery

Research output: Contribution to journal › Review article › peer-review

26 Scopus citations

Abstract

Glioblastoma multiforme (GBM) is a lethal cancer that responds poorly to radiotherapy and chemotherapy. Glioma cancer stem cells (gCSCs) have been shown to recapitulate the characteristic features of GBM and to mediate chemotherapy and radiation resistance. Immunotherapeutic targeting of this cell population holds therapeutic promise but must be considered in the context of the immunosuppressive properties mediated by the gCSC. Recent findings have indicated that this goal will be challenging because the gCSC can suppress both the innate and adaptive immune systems by a variety of gCSC-secreted products and cell-membrane interactions. In this review article, we will attempt to reconcile the disparate research findings regarding the potential of immune targeting of the gCSC and propose several novel solutions.

Original language	English (US)
Pages (from-to)	217-227
Number of pages	11
Journal	Targeted oncology
Volume	5
Issue number	3
DOIs	https://doi.org/10.1007/s11523-010-0151-8
State	Published - Sep 2010

Keywords

Glioblastoma multiforme
Glioma cancer stem cells
Immunotherapy
STAT3

ASJC Scopus subject areas

Oncology
Cancer Research
Pharmacology (medical)

Access to Document

10.1007/s11523-010-0151-8

Cite this

@article{9141a7ab6c8c43e296ff42e95ab24a3c,

title = "Immune therapeutic targeting of glioma cancer stem cells",

abstract = "Glioblastoma multiforme (GBM) is a lethal cancer that responds poorly to radiotherapy and chemotherapy. Glioma cancer stem cells (gCSCs) have been shown to recapitulate the characteristic features of GBM and to mediate chemotherapy and radiation resistance. Immunotherapeutic targeting of this cell population holds therapeutic promise but must be considered in the context of the immunosuppressive properties mediated by the gCSC. Recent findings have indicated that this goal will be challenging because the gCSC can suppress both the innate and adaptive immune systems by a variety of gCSC-secreted products and cell-membrane interactions. In this review article, we will attempt to reconcile the disparate research findings regarding the potential of immune targeting of the gCSC and propose several novel solutions.",

keywords = "Glioblastoma multiforme, Glioma cancer stem cells, Immunotherapy, STAT3",

author = "Hatiboglu, {Mustafa Aziz} and Jun Wei and Wu, {Adam Sauh Gee} and Heimberger, {Amy B.}",

note = "Funding Information: Acknowledgments We thank Lamonne Crutcher for assistance in obtaining tissue specimens and David M. Wildrick, Ph.D., Stephanie Jenkins and Audria Patrick for editorial assistance. Funding for these studies was graciously provided by The Anthony Bullock III Foundation (ABH), the Dr. Marnie Rose Foundation (ABH), the Mitchell Foundation (ABH), the University of Texas M. D. Anderson Cancer Center (ABH), and the National Institutes of Health (CA120813) (ABH).",

year = "2010",

month = sep,

doi = "10.1007/s11523-010-0151-8",

language = "English (US)",

volume = "5",

pages = "217--227",

journal = "Targeted oncology",

issn = "1776-2596",

publisher = "Springer Paris",

number = "3",

}

TY - JOUR

T1 - Immune therapeutic targeting of glioma cancer stem cells

AU - Hatiboglu, Mustafa Aziz

AU - Wei, Jun

AU - Wu, Adam Sauh Gee

AU - Heimberger, Amy B.

N1 - Funding Information: Acknowledgments We thank Lamonne Crutcher for assistance in obtaining tissue specimens and David M. Wildrick, Ph.D., Stephanie Jenkins and Audria Patrick for editorial assistance. Funding for these studies was graciously provided by The Anthony Bullock III Foundation (ABH), the Dr. Marnie Rose Foundation (ABH), the Mitchell Foundation (ABH), the University of Texas M. D. Anderson Cancer Center (ABH), and the National Institutes of Health (CA120813) (ABH).

PY - 2010/9

Y1 - 2010/9

N2 - Glioblastoma multiforme (GBM) is a lethal cancer that responds poorly to radiotherapy and chemotherapy. Glioma cancer stem cells (gCSCs) have been shown to recapitulate the characteristic features of GBM and to mediate chemotherapy and radiation resistance. Immunotherapeutic targeting of this cell population holds therapeutic promise but must be considered in the context of the immunosuppressive properties mediated by the gCSC. Recent findings have indicated that this goal will be challenging because the gCSC can suppress both the innate and adaptive immune systems by a variety of gCSC-secreted products and cell-membrane interactions. In this review article, we will attempt to reconcile the disparate research findings regarding the potential of immune targeting of the gCSC and propose several novel solutions.

AB - Glioblastoma multiforme (GBM) is a lethal cancer that responds poorly to radiotherapy and chemotherapy. Glioma cancer stem cells (gCSCs) have been shown to recapitulate the characteristic features of GBM and to mediate chemotherapy and radiation resistance. Immunotherapeutic targeting of this cell population holds therapeutic promise but must be considered in the context of the immunosuppressive properties mediated by the gCSC. Recent findings have indicated that this goal will be challenging because the gCSC can suppress both the innate and adaptive immune systems by a variety of gCSC-secreted products and cell-membrane interactions. In this review article, we will attempt to reconcile the disparate research findings regarding the potential of immune targeting of the gCSC and propose several novel solutions.

KW - Glioblastoma multiforme

KW - Glioma cancer stem cells

KW - Immunotherapy

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=78049239954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049239954&partnerID=8YFLogxK

U2 - 10.1007/s11523-010-0151-8

DO - 10.1007/s11523-010-0151-8

M3 - Review article

C2 - 20737294

AN - SCOPUS:78049239954

SN - 1776-2596

VL - 5

SP - 217

EP - 227

JO - Targeted oncology

JF - Targeted oncology

IS - 3

ER -

Immune therapeutic targeting of glioma cancer stem cells

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this